600 related articles for article (PubMed ID: 17157662)
41. Eosinophilic esophagitis: from the case report to the evidence.
Villalta D; Baragiotta AM
Eur Ann Allergy Clin Immunol; 2008 Jun; 40(2):53-60. PubMed ID: 18717053
[TBL] [Abstract][Full Text] [Related]
42. Infiltrating eosinophils and eotaxin: their association with idiopathic eosinophilic esophagitis.
Fujiwara H; Morita A; Kobayashi H; Hamano K; Fujiwara Y; Hirai K; Yano M; Naka T; Saeki Y
Ann Allergy Asthma Immunol; 2002 Oct; 89(4):429-32. PubMed ID: 12392390
[TBL] [Abstract][Full Text] [Related]
43. Pharmacologic treatment of eosinophilic esophagitis.
Liacouras CA
Gastrointest Endosc Clin N Am; 2008 Jan; 18(1):169-78; xi. PubMed ID: 18061110
[TBL] [Abstract][Full Text] [Related]
44. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome.
Kim S; Marigowda G; Oren E; Israel E; Wechsler ME
J Allergy Clin Immunol; 2010 Jun; 125(6):1336-43. PubMed ID: 20513524
[TBL] [Abstract][Full Text] [Related]
45. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture.
Daikh BE; Ryan CK; Schwartz RH
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):23-7. PubMed ID: 12546333
[TBL] [Abstract][Full Text] [Related]
46. Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis.
Otani IM; Anilkumar AA; Newbury RO; Bhagat M; Beppu LY; Dohil R; Broide DH; Aceves SS
J Allergy Clin Immunol; 2013 Jun; 131(6):1576-82. PubMed ID: 23623266
[TBL] [Abstract][Full Text] [Related]
47. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
48. Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder.
Aceves SS; Newbury RO; Dohil R; Schwimmer J; Bastian JF
J Clin Gastroenterol; 2007 Mar; 41(3):252-6. PubMed ID: 17426462
[TBL] [Abstract][Full Text] [Related]
49. Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis.
Müller S; Pühl S; Vieth M; Stolte M
Endoscopy; 2007 Apr; 39(4):339-44. PubMed ID: 17427070
[TBL] [Abstract][Full Text] [Related]
50. Translational research on the pathogenesis of eosinophilic esophagitis.
Chehade M
Gastrointest Endosc Clin N Am; 2008 Jan; 18(1):145-56; x. PubMed ID: 18061108
[TBL] [Abstract][Full Text] [Related]
51. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate.
Remedios M; Campbell C; Jones DM; Kerlin P
Gastrointest Endosc; 2006 Jan; 63(1):3-12. PubMed ID: 16377308
[TBL] [Abstract][Full Text] [Related]
52. Histopathologic variability in children with eosinophilic esophagitis.
Shah A; Kagalwalla AF; Gonsalves N; Melin-Aldana H; Li BU; Hirano I
Am J Gastroenterol; 2009 Mar; 104(3):716-21. PubMed ID: 19209168
[TBL] [Abstract][Full Text] [Related]
53. IL-5 promotes eosinophil trafficking to the esophagus.
Mishra A; Hogan SP; Brandt EB; Rothenberg ME
J Immunol; 2002 Mar; 168(5):2464-9. PubMed ID: 11859139
[TBL] [Abstract][Full Text] [Related]
54. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels.
Stein ML; Villanueva JM; Buckmeier BK; Yamada Y; Filipovich AH; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2008 Jun; 121(6):1473-83, 1483.e1-4. PubMed ID: 18410960
[TBL] [Abstract][Full Text] [Related]
55. Increased esophageal regulatory T cells and eosinophil characteristics in children with eosinophilic esophagitis and gastroesophageal reflux disease.
Tantibhaedhyangkul U; Tatevian N; Gilger MA; Major AM; Davis CM
Ann Clin Lab Sci; 2009; 39(2):99-107. PubMed ID: 19429794
[TBL] [Abstract][Full Text] [Related]
56. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids.
Liacouras CA; Wenner WJ; Brown K; Ruchelli E
J Pediatr Gastroenterol Nutr; 1998 Apr; 26(4):380-5. PubMed ID: 9552132
[TBL] [Abstract][Full Text] [Related]
57. [Dysregulation of cooperative interactions of immunocytes and eosinophils in the mechanism of development of eosinophilia in Opisthorhis felineus invasion].
Litvinova LS; Riazantseva NV; Novitskiĭ VV
Med Parazitol (Mosk); 2008; (3):13-7. PubMed ID: 18819423
[TBL] [Abstract][Full Text] [Related]
58. [Eosinophilic esophagitis--pathogenesis, clinical presentation and therapeutic management].
von Arnim U; Mönkemüller K; Malfertheiner P; Straumann A
Z Gastroenterol; 2007 Dec; 45(12):1257-63. PubMed ID: 18080228
[TBL] [Abstract][Full Text] [Related]
59. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups.
Kapel RC; Miller JK; Torres C; Aksoy S; Lash R; Katzka DA
Gastroenterology; 2008 May; 134(5):1316-21. PubMed ID: 18471509
[TBL] [Abstract][Full Text] [Related]
60. Reslizumab for pediatric eosinophilic esophagitis.
Walsh GM
Immunotherapy; 2010 Jul; 2(4):461-5. PubMed ID: 20636000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
